Incyte (LTS:0J9P) Cyclically Adjusted Book per Share: $15.86 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0J9P Incyte Corp LTS:0J9P
90 GF Score
Price $117.42
GF Value $99.11
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Cyclically Adjusted Book per Share?

Incyte LTS:0J9P +1.12% 90 Cyclically Adjusted Book per Share is $15.86 as of Mar. 2026. GuruFocus rates LTS:0J9P with a GF Score™ of 90/100 and a GF Value™ of $99.11 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Incyte's adjusted book value per share for the three months ended in Mar. 2026 was $28.122. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $15.86 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Incyte's average Cyclically Adjusted Book Growth Rate was 21.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 24.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 33.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Incyte was 80.80% per year. The lowest was -56.10% per year. And the median was 1.05% per year.

As of today (2026-07-20), Incyte's current stock price is $117.42. Incyte's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $15.86. Incyte's Cyclically Adjusted PB Ratio of today is 7.40.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Incyte was 1233.83. The lowest was 4.32. And the median was 12.50.


Incyte  (LTS:0J9P) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Incyte's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=117.42/15.86
=7.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Incyte was 1233.83. The lowest was 4.32. And the median was 12.50.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Incyte Cyclically Adjusted Book per Share Related Terms


Incyte Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Incyte's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Cyclically Adjusted Book per Share Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.42 7.69 10.21 12.51 15.11

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.99 13.74 14.47 15.11 15.86

LTS:0J9P vs INSM, BNTX, ROIV: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Incyte's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted PB Ratio falls into.


LTS:0J9P
90GF Score
Incyte Corp LTS:0J9P
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=28.122/330.2130*330.2130
=28.122

Current CPI (Mar. 2026) = 330.2130.

Incyte Quarterly Data

Book Value per Share CPI Adj_Book
201606 1.581 241.018 2.166
201609 1.965 241.428 2.688
201612 2.221 241.432 3.038
201703 4.722 243.801 6.396
201706 4.994 244.955 6.732
201709 8.330 246.819 11.144
201712 7.718 246.524 10.338
201803 7.684 249.554 10.168
201806 8.158 251.989 10.690
201809 8.474 252.439 11.085
201812 9.030 251.233 11.869
201903 9.731 254.202 12.641
201906 10.459 256.143 13.483
201909 11.248 256.759 14.466
201912 12.020 256.974 15.446
202003 8.932 258.115 11.427
202006 10.752 257.797 13.772
202009 10.922 260.280 13.857
202012 11.897 260.474 15.082
202103 12.406 264.877 15.466
202106 13.319 271.696 16.188
202109 14.255 274.310 17.160
202112 17.052 278.802 20.196
202203 17.448 287.504 20.040
202206 18.412 296.311 20.519
202209 19.000 296.808 21.138
202212 19.619 296.797 21.828
202303 20.006 301.836 21.887
202306 21.227 305.109 22.974
202309 22.005 307.789 23.608
202312 23.139 306.746 24.909
202403 24.024 312.332 25.399
202406 15.645 314.175 16.444
202409 16.448 315.301 17.226
202412 17.823 315.605 18.648
202503 18.926 319.799 19.542
202506 21.486 322.561 21.996
202509 23.715 324.800 24.110
202512 26.038 324.054 26.533
202603 28.122 330.213 28.122

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $15.86 mean?
Incyte (LTS:0J9P) has a Cyclically Adjusted Book per Share of $15.86 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Incyte and its competitors.
Is Incyte's Cyclically Adjusted Book per Share too high?
Incyte's current Cyclically Adjusted Book per Share is $15.86. Overall, Incyte has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Cyclically Adjusted Book per Share compare to INSM and BNTX?
Incyte's Cyclically Adjusted Book per Share of $15.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Incyte and its competitors. Incyte's current Cyclically Adjusted Book per Share is $15.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (LTS:0J9P) is currently considered Modestly Overvalued. The stock's GF Value™ is $99.11, compared to a current price of $117.42 — trading 18.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is $15.86. Incyte's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Incyte (LTS:0J9P), the current Cyclically Adjusted Book per Share is $15.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (LTS:0J9P) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of $117.42 is trading 18.5% above its estimated GF Value™ of $99.11. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for LTS:0J9P:

  • Cyclically Adjusted Book per Share: $15.86
  • GF Value™: $99.11 vs. price of $117.42 (18.5% above fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the LTS:0J9P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
90GF Score

Get the complete analysis for LTS:0J9P

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$117.42
Price
$99.11
GF Value